BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG

Scinai Immunotherapeutics Ltd.

Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.
Within 45 days of June 4, 2023, BiondVax will issue 17,000 American Depositary Shares to licensors, with a 1-year lock-up.
Milestone payments due upon IND submission and clinical study initiations; royalties on net sales apply.
BiondVax must submit an IND by June 30, 2025, or face termination by December 31, 2026, unless extended via EUR 500,000 payments.
Plans to initiate a preclinical in vivo efficacy study in 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Scinai Immunotherapeutics Ltd. entered into License Agreement with Max-Planck-Innovation GmbH and the University Medical Center Gottingen (effective 2023-06-04).

Action: entry
Agreement: license
Counterparty: Max-Planck-Innovation GmbH and the University Medical Center Gottingen
Effective: 2023-06-04

Exact text from the filing

On June 4, 2023, BiondVax Pharmaceuticals Ltd. (the “Company” or “BiondVax”) entered into a License Agreement (the “License Agreement”) with the Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany(“MI”) and the University Medical Center Gottingen (“UMG”) to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) (the “Target”) as treatments for all potential indications.

View on SEC.gov

Browse all material agreements →

Scinai Immunotherapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001213900-23-047493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.